Supriya Lifescience Limited (NSE:SUPRIYA)

Market Cap	55.04B -4.9%
Revenue (ttm)	7.35B +9.7%
Net Income	1.85B +6.2%
EPS	23.04 +6.4%
Shares Out	80.48M
PE Ratio	29.68
Forward PE	23.27
Dividend	1.00 (0.15%)
Ex-Dividend Date	Sep 4, 2025

Volume	83,465
Average Volume	228,294
Open	675.80
Previous Close	675.80
Day's Range	675.80 - 700.55
52-Week Range	545.50 - 832.40
Beta	0.45
RSI	54.64
Earnings Date	May 26, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 515
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUPRIYA

Financial Performance

In fiscal year 2025, Supriya Lifescience's revenue was 6.96 billion, an increase of 22.12% compared to the previous year's 5.70 billion. Earnings were 1.88 billion, an increase of 57.80%.